Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 18 de 18
Filtrar
Más filtros












Base de datos
Intervalo de año de publicación
1.
Anticancer Res ; 43(4): 1581-1589, 2023 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-36974788

RESUMEN

BACKGROUND: Biphenotypic sinonasal sarcoma (BSNS) is a rare spindle cell sarcoma distinctly arising in the sinonasal area, with dual myogenic and neural differentiation, and characterised by the presence of PAX3 gene fusion, typically with MAML3. Although the majority may be indolent, up to 25% of cases reported in the literature are locally aggressive, with invasion of adjacent critical structures in the head and neck region. CASE REPORT: We report 3 cases of BSNS reviewed at our institution between 2016-2020 in addition to the current literature. Patient 1 underwent surgery followed by adjuvant radiotherapy but relapsed 24 months later and was not fit for systemic anticancer therapy and managed with palliative care. Due to comorbidities, patient 2 was recommended for active surveillance, with a view to intervening with radiotherapy should there be evidence of clinical progression. At 60 months, the nasal cavity mass remained stable on serial imaging. Patient 3 underwent primary surgical R0 resection and was offered adjuvant post operative radiotherapy 60 Gy/30 fractions/6 weeks but opted for active surveillance and has no clinical or radiological evidence of recurrence 22 months after surgery. CONCLUSION: The primary management for BSNS is surgical resection. We recommend discussing the role of postoperative adjuvant radiotherapy 60 Gy/30 fractions/6 weeks in patients who are fit for treatment. In clinical practice, dose levels will be constrained by surrounding normal tissues. At present, the role of systemic anticancer therapy is undefined. A prospective registry of ultra-rare cases may provide an evidence base with which to select optimal treatment strategies for BSNS in the future.


Asunto(s)
Neoplasias de los Senos Paranasales , Sarcoma , Humanos , Factor de Transcripción PAX3 , Fenotipo , Inmunohistoquímica , Neoplasias de los Senos Paranasales/diagnóstico , Neoplasias de los Senos Paranasales/terapia , Sarcoma/diagnóstico , Sarcoma/genética , Sarcoma/terapia
2.
Horm Metab Res ; 53(10): 672-675, 2021 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-34233374

RESUMEN

Ethnic differences in intact parathyroid hormone (iPTH) at similar total 25 hydroxyvitamin D [25(OH)D] concentrations have been reported between US resident Whites, Blacks, and Hispanics, but this has not been studied between South Asians and Whites. We, therefore, compared the iPTH relationship to 25(OH)D in UK resident South Asians and Whites. A comparative, cross-sectional observational study in which demographic and laboratory data on South Asian and White residents of Wolverhampton, UK were analyzed. Log-log models measured the association between 25(OH)D and the interaction term of ethnicity and iPTH. Seven hundred and seventy-two patients consisting of 315 white subjects (208 women) and 457 South Asian subjects (331 women) were studied. Compared to South Asians, White subjects were older, had higher serum concentrations of 25(OH)D, creatinine (lower eGFR), adjusted calcium and magnesium, but similar concentrations of iPTH and phosphate. In an adjusted model, variables significantly associated with 25(OH)D included age, creatinine, adjusted calcium and ethnicity; but not iPTH and the interaction term of ethnicity and iPTH (beta coefficient -0.071, 95% CI -0.209, 0.067, p=0.32). In our study cohort, iPTH was not, per se, influenced by 25 (OH)D. We found no ethnic differences in the association between iPTH and 25(OH)D between South Asians and White UK residents.


Asunto(s)
Etnicidad/estadística & datos numéricos , Hormona Paratiroidea/sangre , Vitamina D/análogos & derivados , Adulto , Anciano , Asia/etnología , Pueblo Asiatico/estadística & datos numéricos , Estudios de Cohortes , Estudios Transversales , Femenino , Humanos , Masculino , Persona de Mediana Edad , Reino Unido/epidemiología , Vitamina D/sangre , Población Blanca/estadística & datos numéricos
3.
Eur J Surg Oncol ; 47(10): 2595-2601, 2021 10.
Artículo en Inglés | MEDLINE | ID: mdl-33966946

RESUMEN

BACKGROUND: Primary leiomyosarcoma (LMS) of the gastrointestinal (GI) tract is rare. Limited literature exists regarding the clinical characteristics and outcome for patients with localised and metastatic disease. METHODS: A retrospective chart review was performed for patients greater than 18 years of age diagnosed with GI LMS at The Royal Marsden Hospital between 1 January 2000-1 May 2020. Descriptive statistics were performed. Patients were censored at data cut-off date of 27 June 2020. RESULTS: Forty-six patients with a median age at diagnosis of 54 years (range 25-85) were identified. Fifteen percent (n = 7) of patients previously received abdominal radiation for an unrelated cancer. All patients with localised disease (n = 36) had resection with oncological margins. For patients who underwent potentially curative surgery, median recurrence-free survival (mRFS) was 13 months (0.4-183 months), and half of these patients (n = 18) developed recurrent disease post resection (distant n = 16, local n = 2). Median overall survival (mOS) was 27 months for patients with distant recurrence. Twenty-one percent (n = 10) of patients presented with synchronous metastatic disease and their mOS was 19 months. Median progression-free survival (mPFS) for patients treated with conventional chemotherapy ranged from 2.0 to 8.0 months. CONCLUSION: The risk of recurrence is significant, and recurrence-free survival was short even with complete oncologic resection. The relationship of prior abdominal radiotherapy to the development of GI LMS warrants further investigation. Outcomes with systemic therapy for metastatic disease were poor and there is a need for the development of more effective systemic therapies.


Asunto(s)
Neoplasias Gastrointestinales/patología , Neoplasias Gastrointestinales/terapia , Leiomiosarcoma/secundario , Leiomiosarcoma/terapia , Recurrencia Local de Neoplasia/terapia , Neoplasias Inducidas por Radiación/fisiopatología , Neoplasias Inducidas por Radiación/terapia , Adulto , Anciano , Anciano de 80 o más Años , Antineoplásicos/uso terapéutico , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Quimioterapia Adyuvante , Femenino , Humanos , Estimación de Kaplan-Meier , Masculino , Márgenes de Escisión , Metastasectomía , Persona de Mediana Edad , Supervivencia sin Progresión , Radioterapia/efectos adversos , Estudios Retrospectivos , Tasa de Supervivencia
4.
Int J Surg Pathol ; 29(1): 4-20, 2021 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-32909482

RESUMEN

Gynecological sarcomas represent 3% to 4% of all gynecological malignancies and 13% of all sarcomas. The uterus is the most frequent primary site (83%); less frequently sarcomas are diagnosed originating from the ovary (8%), vulva and vagina (5%), and other gynecologic organs (2%). As the classification of gynecologic sarcomas continues to diversify, so does the management. Accurate histopathologic diagnosis, utilizing appropriate ancillary immunohistochemical and molecular analysis, could lead to a more personalized approach. However, there are subtypes that require further definition, with regard to putative predictive markers and optimal management. The aim of this review is to highlight the importance of accurate diagnosis and classification of gynecologic sarcoma subtypes by the surgical pathologist in order to provide more tailored systemic treatment, and to highlight the increasing importance of close collaboration between the pathologist and the oncologist.


Asunto(s)
Biomarcadores de Tumor/análisis , Quimioradioterapia Adyuvante/métodos , Neoplasias de los Genitales Femeninos/diagnóstico , Procedimientos Quirúrgicos Ginecológicos/métodos , Sarcoma/diagnóstico , Femenino , Neoplasias de los Genitales Femeninos/mortalidad , Neoplasias de los Genitales Femeninos/patología , Neoplasias de los Genitales Femeninos/terapia , Humanos , Inmunohistoquímica , Técnicas de Diagnóstico Molecular , Clasificación del Tumor , Ovario/patología , Supervivencia sin Progresión , Sarcoma/mortalidad , Sarcoma/patología , Sarcoma/terapia , Útero/patología , Vagina/patología , Vulva/patología
6.
Int J Surg Pathol ; 29(2): 179-181, 2021 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-32615834

RESUMEN

EWSR1-SMAD3-positive fibroblastic tumor is a recently characterized neoplasm with distinct clinicopathologic features and recurrent EWSR1-SMAD3 gene fusion. ESFT typically presents as a small, painless tumor in extremity subcutaneous tissues. Their behavior is benign, although they are prone to local recurrence. They typically comprise two components: intersecting fascicles of overlapping, uniform plump spindle cells, and less cellular hyalinized areas containing stippled calcifications. Immunohistochemically, the cells consistently show diffuse ERG nuclear expression, while other markers are negative. The morphology of this neoplasm can lead to histologic confusion with both benign and malignant soft tissue tumors, including monophasic synovial sarcoma, malignant peripheral nerve sheath tumor, and spindle cell sarcoma, not otherwise specified. Correct identification of ESFT is critical, most importantly to avoid unnecessary overtreatment as sarcoma.


Asunto(s)
Biomarcadores de Tumor/genética , Proteínas de Fusión Oncogénica/genética , Proteína EWS de Unión a ARN/genética , Proteína smad3/genética , Neoplasias de los Tejidos Blandos/diagnóstico , Adulto , Diagnóstico Diferencial , Femenino , Secuenciación de Nucleótidos de Alto Rendimiento , Humanos , Sarcoma/diagnóstico , Sarcoma/patología , Neoplasias de los Tejidos Blandos/genética , Neoplasias de los Tejidos Blandos/patología , Falanges de los Dedos del Pie
7.
Sarcoma ; 2020: 9810170, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-33061792

RESUMEN

Soft tissue tumors are diagnostically challenging, and it is recommended that these are reported or reviewed by specialist soft tissue pathologists. We present our experience with second-opinion (consultation) cases in a specialist tertiary sarcoma center. The aim of this study was to determine areas of diagnostic difficulty in soft tissue pathology. We assessed 581 second-opinion cases which were reviewed by two experienced pathologists in a period of one year. There was 62% concordance between the original and the second-opinion diagnosis, with diagnostic discrepancy in 38%. The largest group of soft tissue neoplasms received for second opinion was fibroblastic/myofibroblastic tumors, and most major diagnostic problems were encountered in adipocytic and so-called "fibrohistiocytic" tumors. Major diagnostic errors impacting management were found in 148 cases (25%). Morphologic assessment of tumors, judicious use of molecular techniques, newer immunostains and their interpretation, along with importance of knowledge of rarer entities were found to be most useful in avoiding errors.

8.
Rare Tumors ; 12: 2036361320950862, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-32913618

RESUMEN

Epithelioid malignant peripheral nerve sheath tumor (EMPNST, malignant epithelioid schwannoma) is a rare variant of malignant peripheral nerve sheath tumor that has morphologic and immunophenotypic overlap with a variety of epithelioid neoplasms. Because of its rarity it may be potentially underrecognized. We describe a case arising in the subcutis of the thigh in a 25 year-old female, and discuss the pathologic features and differential diagnosis.

9.
Int J Surg Pathol ; 28(8): 879-881, 2020 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-32608310

RESUMEN

Superficial CD34-positive fibroblastic tumor (SCPFT) is a recently described entity that, despite significant pleomorphism, carries a good prognosis. We briefly describe this tumor and its principal differential diagnoses. Recognition of SCPFTs, including the clinical context in which they arise, is important to avoid confusion with other pleomorphic soft tissue tumors, particularly neoplasms in the group of pleomorphic sarcomas, which are typically aggressive tumors that could lead to unnecessary overtreatment.


Asunto(s)
Antígenos CD34/análisis , Biomarcadores de Tumor/análisis , Dermis/patología , Neoplasias de Tejido Fibroso/diagnóstico , Neoplasias Cutáneas/diagnóstico , Antígenos CD34/metabolismo , Biomarcadores de Tumor/metabolismo , Biopsia , Dermis/citología , Diagnóstico Diferencial , Fibroblastos/patología , Humanos , Masculino , Neoplasias de Tejido Fibroso/patología , Sarcoma/diagnóstico , Neoplasias Cutáneas/patología , Muslo , Adulto Joven
13.
Rare Tumors ; 10: 2036361318782626, 2018.
Artículo en Inglés | MEDLINE | ID: mdl-29977483

RESUMEN

Myxoinflammatory fibroblastic sarcoma is a rare malignant soft tissue neoplasm that typically arises on the distal extremities of adults. It usually behaves in a low-grade manner and its characteristic histology is of a lobulated proliferation of moderately atypical spindled to epithelioid cells, vacuolated cells, and enlarged or bizarre cells with prominent nucleoli, dispersed within myxoid stroma containing a mixed inflammatory cell infiltrate. The etiology of myxoinflammatory fibroblastic sarcoma remains unknown with no definite causal factors identified. We describe a case of myxoinflammatory fibroblastic sarcoma arising in the foot of a 77-year-old female, which rapidly recurred locally after initial excision and which arose 10 years after renal transplantation. The neoplasm also showed intermingled areas of hemosiderotic fibrolipomatous tumor. The patient also had multifocal areas of squamous cell carcinoma in situ of the foot and hand, in keeping with the clinical context of immune deficiency. This is the second case of myxoinflammatory fibroblastic sarcoma reported to occur after transplantation, but additionally shows hybrid features of hemosiderotic fibrolipomatous tumor, highlights immunocompromise/immunosuppressive therapy as a possible etiologic factor in their development, and adds to the growing number of myxoinflammatory fibroblastic sarcoma that has demonstrated aggressive behavior.

16.
Int J Surg Pathol ; 25(1): 51-53, 2017 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-27422468

RESUMEN

Gastrointestinal stromal tumors (GISTs) are potentially aggressive mesenchymal neoplasms with spindle cell, epithelioid, or mixed morphology. They typically express CD117, DOG1, and CD34 and can be diffusely and strongly positive for h-caldesmon. Leiomyomas are benign smooth muscle neoplasms that can arise in a variety of visceral and soft tissue sites, including the gastrointestinal tract. We illustrate a case of a neoplasm of the gastroesophageal junction that was clinically suspected to be a GIST. Histology showed a tumor composed of ovoid and spindle cells arranged in short intersecting fascicles, which was positive for desmin, smooth muscle actin, and h-caldesmon, with a prominent interspersed subpopulation of CD117- and DOG1-positive elongated or dendritic-like cells. These features were of leiomyoma with entrapped interstitial cells of Cajal (ICC). The recognition of possible entrapment of ICC in leiomyomas as a potential mimic of GIST is important for correct treatment and prognostication.


Asunto(s)
Neoplasias Esofágicas/diagnóstico , Neoplasias Esofágicas/patología , Células Intersticiales de Cajal/patología , Leiomioma/diagnóstico , Leiomioma/patología , Biomarcadores de Tumor/análisis , Diagnóstico Diferencial , Tumores del Estroma Gastrointestinal/diagnóstico , Tumores del Estroma Gastrointestinal/patología , Humanos , Inmunohistoquímica
17.
Int J Surg Pathol ; 24(7): 620-2, 2016 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-27272683

RESUMEN

Well-differentiated liposarcoma (WDL) can show a morphologic spectrum, including lipoma-like, sclerosing and inflammatory subtypes. It does not metastasize but can dedifferentiate, acquiring metastatic potential. Hibernomas are benign neoplasms that show variable differentiation toward brown fat, and can sometimes occur in the abdomen or retroperitoneum. We illustrate a case of retroperitoneal WDL that showed extensive hibernoma-like morphology, with sheets of multivacuolated adipocytes of varying sizes, with abundant cytoplasm and numerous lipid vacuoles or granular eosinophilic cytoplasm. However, very focally there were fibrous septa containing spindle cells with enlarged, hyperchromatic, mildly pleomorphic nuclei. Further sampling showed areas of typical WDL, with lobules of mature fat intersected by fibrous septa containing atypical, enlarged spindle cells, as well as small foci of dedifferentiation. Immunohistochemistry for CDK4 and p16 showed strong and diffuse nuclear expression in the hibernoma-like areas, and fluorescence in situ hybridization showed MDM2 gene amplification, all in keeping with WDL. We highlight hibernoma-like morphology as part of the histologic spectrum of WDL, and recognition of this variant is important for correct treatment and prognostication.


Asunto(s)
Lipoma/diagnóstico , Liposarcoma/diagnóstico , Neoplasias Retroperitoneales/diagnóstico , Biomarcadores de Tumor/análisis , Diagnóstico Diferencial , Humanos , Inmunohistoquímica , Lipoma/patología , Liposarcoma/patología , Neoplasias Retroperitoneales/patología
18.
Ann Clin Biochem ; 50(Pt 1): 80-2, 2013 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-23086978

RESUMEN

We report two patients with markedly elevated 24-h urine 5-hydroxyindoleacetic acid (5-HIAA) excretion due to over-the-counter (OTC) self-medication with 5-hydroxytryptophan (5-HTP). It is important to recognize that OTC medication may cause increased 'false-positive' 5-HIAA excretion to prevent undue patient anxiety and unnecessary further investigation for carcinoid disease. Discordance between chromogranin A and 24-h urine 5-HIAA results should alert to the possibility of false-positive or -negative laboratory results.


Asunto(s)
5-Hidroxitriptófano/metabolismo , Ácido Hidroxiindolacético/orina , Medicamentos sin Prescripción/metabolismo , 5-Hidroxitriptófano/administración & dosificación , Anciano , Cromatografía Líquida de Alta Presión , Cromogranina A/sangre , Reacciones Falso Positivas , Femenino , Humanos , Síndrome Carcinoide Maligno/diagnóstico , Síndrome Carcinoide Maligno/orina , Persona de Mediana Edad , Medicamentos sin Prescripción/administración & dosificación , Serotonina/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...